Blair William & Co. IL Sells 38,628 Shares of Align Technology, Inc. $ALGN

Blair William & Co. IL lowered its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 52.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 34,979 shares of the medical equipment provider’s stock after selling 38,628 shares during the period. Blair William & Co. IL’s holdings in Align Technology were worth $6,623,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas bought a new stake in shares of Align Technology in the 1st quarter valued at about $1,647,000. Asset Management One Co. Ltd. lifted its stake in shares of Align Technology by 14.5% in the 1st quarter. Asset Management One Co. Ltd. now owns 31,624 shares of the medical equipment provider’s stock valued at $5,024,000 after acquiring an additional 4,009 shares during the last quarter. Czech National Bank lifted its stake in shares of Align Technology by 3.3% in the 2nd quarter. Czech National Bank now owns 16,654 shares of the medical equipment provider’s stock valued at $3,153,000 after acquiring an additional 537 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Align Technology in the 1st quarter valued at about $20,194,000. Finally, Parallel Advisors LLC lifted its stake in shares of Align Technology by 66.0% in the 2nd quarter. Parallel Advisors LLC now owns 1,044 shares of the medical equipment provider’s stock valued at $198,000 after acquiring an additional 415 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Insider Buying and Selling at Align Technology

In other news, CEO Joseph M. Hogan bought 7,576 shares of Align Technology stock in a transaction on Friday, August 1st. The shares were purchased at an average price of $131.49 per share, for a total transaction of $996,168.24. Following the acquisition, the chief executive officer owned 184,945 shares of the company’s stock, valued at approximately $24,318,418.05. The trade was a 4.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.66% of the company’s stock.

Align Technology Stock Performance

ALGN stock opened at $125.79 on Monday. Align Technology, Inc. has a fifty-two week low of $122.00 and a fifty-two week high of $246.19. The business’s 50 day moving average price is $135.61 and its two-hundred day moving average price is $164.38. The company has a market capitalization of $9.12 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 1.43 and a beta of 1.70.

Align Technology (NASDAQ:ALGN) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the company posted $2.41 EPS. The firm’s revenue was down 1.6% on a year-over-year basis. Align Technology has set its Q3 2025 guidance at EPS. Sell-side analysts forecast that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology declared that its board has authorized a share repurchase program on Tuesday, August 5th that permits the company to buyback $200.00 million in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 2% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ALGN shares. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 30th. Mizuho set a $210.00 target price on Align Technology in a research note on Thursday, July 31st. Piper Sandler reduced their price target on Align Technology from $250.00 to $190.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. Wells Fargo & Company reduced their price target on Align Technology from $246.00 to $199.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. Finally, Morgan Stanley restated an “equal weight” rating and set a $154.00 price target (down previously from $249.00) on shares of Align Technology in a report on Thursday, July 31st. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $200.00.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.